| Title | Author(s) | Year | View Count |
 | Trend of colorectal cancer in Hong Kong: 1983-2006 | Yee, YK; Gu, Q; Hung, I; Tan, VPY; Chan, P; Hsu, A; Pang, R; Lam, CSC; Wong, BCY | 2010 | 104 |
| Epidemiology of colorectal cancer in Asia | Yee, YK; Tan, VPY; Chan, P; Hung, IFN; Pang, R; Wong, BCY | 2009 | 89 |
| Prevalence and time trend of intestinal metaplasia in Hong Kong | Yee, YK; Wong, KW; Hui, CK; Chan, CK; Chan, AOO; Lam, SK; Fung, FMY; Hung, I; Wong, BCY | 2009 | 153 |
| Adenocarcinoma of the esophagogastric junction: Do we see more or less? | Yee, YK; Wong, BCY | 2008 | 75 |
| Factors affecting physicians' practices related to Helicobacter pylori infection: Effect of experience and mode of practice | Yee, YK; Cheung, TK; Gu, Q; Chan, P; But, D; Hung, IFN; Chan, CK; Yuen, MF; Wong, BCY | 2008 | 103 |
| Clinical trial: Levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection | Yee, YK; Cheung, TK; Chu, KM; Chan, CK; Fung, J; Chan, P; But, D; Hung, I; Chan, AOO; Yuen, MF; Hsu, A; Wong, BCY | 2007 | 67 |
| Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection | Wong, WM; Gu, Q; Chu, KM; Yee, YK; Fung, FMY; Tong, TSM; Chan, AOO; Lai, KC; Chan, CK; Wong, BCY | 2006 | 72 |
 | Lansoprazole, levofloxacin and amoxicillin triple therapy versus quadruple therapy as second-line treatment of resistant Helicobacter pylori infection | Wong, WMR; Gu, Q; Chu, KM; Yee, YK; Fung, FMY; Tong, SM; Chan, OOA; Lai, KC; Chan, CK; Wong, BCY | 2006 | 132 |
 | Randomised controlled study of rabeprazole, levofloxacin and rifabutin triple therapy versus quadruple therapy as second-line treatment of Helicobacter pylori infection | Wong, WM; Gu, Q; Lam, SK; Fung, FMY; Lai, KC; Hu, WHC; Yee, YK; Chan, CK; Xia, HHX; Yuen, MF; Wong, BCY | 2003 | 213 |
| Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection | Wong, WM; Gu, O; Lam, SK; Fung, FMY; Lai, KC; Hu, WHC; Yee, YK; Chan, CK; Xia, HHX; Yuen, MF; Wong, BCY | 2003 | 70 |
| Chinese tea consumption and lower risk of Helicobacter infection | Yee, YK; Koo, MWL; Szeto, ML | 2002 | 108 |
| Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients | Wong, WM; Wong, BCY; Hung, WK; Yee, YK; Yip, AWC; Szeto, ML; Fung, FMY; Tong, TSM; Lai, KC; Hu, WHC; Yuen, MF; Lam, SK | 2002 | 313 |
| Evaluation of five commercial serological tests for detection of Helicobacter pylori infection in Chinese | Szeto, ML; Lee, CK; Yee, YK; Li, KF; Lee, WK; Lee, CC; Que, TL; Wong, BCY | 2001 | 106 |
| Evaluation of five commercial serological tests for the detection of Helicobacter pylori infection in Chinese | Szeto, ML; Lee, CK; Yee, YK; Li, KF; Lee, WK; Lee, CC; Que, TL; Wong, BCY | 2001 | 60 |
| Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection | Wong, BCY; Wong, WM; Yee, YK; Hung, WK; Yip, AWC; Szeto, ML; Li, KF; Lau, P; Fung, FMY; Tong, TSM; Lai, KC; Hu, WHC; Yuen, MF; Hui, CK; Lam, SK | 2001 | 79 |
| Rabeprazole based 3-day and 7-day triple therapy vs 7-day omeprazole based triple therapy for the treatment of Helicobacter pylori infection | Fung, FMY; Wong, WM; Lam, SK; Yee, YK; Hung, WK; Yip, WC; Szeto, ML; Tong, SM; Lai, KC; Hu, HC; Hui, CK; Wong, BCY | 2001 | 128 |
| Effect of Chinese tea consumption on Helicobacter pylori infection | Yee, YK; Koo, MWL; Szeto, ML | 2000 | 93 |
| Anti-Helicobacter pylori activity in Chinese tea: In vitro study | Yee, YK; Koo, MWL | 2000 | 36 |
|
